Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

26 juin 2024 10h15 HE | Source: COUR Pharmaceuticals

COUR Pharmaceuticals Appoints Tim Walbert to its Board of Directors

CHICAGO, June 26, 2024 (GLOBE NEWSWIRE) -- COUR Pharmaceuticals, a clinical-stage biotechnology company focused on the development of ﬁrst-in-class, disease-modifying therapies designed to induce...
21 mai 2024 08h00 HE | Source: COUR Pharmaceuticals

COUR Pharmaceuticals Appoints Paul M. Peloso, MD, as Chief Medical Officer

CHICAGO, May 21, 2024 (GLOBE NEWSWIRE) -- COUR Pharmaceuticals, a clinical-stage biotechnology company focused on the development of ﬁrst-in-class, disease-modifying therapies designed to induce...
30 janv. 2024 06h00 HE | Source: COUR Pharmaceuticals

COUR Pharmaceuticals Secures $105 Million in Series A Financing Co-Led by Lumira Ventures and Alpha Wave Ventures

Funds will be used to support the advancement of COUR’s Myasthenia Gravis (MG) and Type 1 Diabetes (T1D) product candidates into Phase 2a clinical trialsParticipating investors include Roche Venture...
08 févr. 2023 08h00 HE | Source: COUR Pharmaceuticals

COUR Pharmaceuticals Announces Biotechnology Industry Veteran Robert F. Carey Joins Board of Directors as Lead Independent Director

CHICAGO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- COUR Pharmaceuticals, a clinical-stage biotechnology company developing novel immune-modifying nanoparticles designed to reprogram the immune system, today...